Zhangali A. Bekbol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhangali A. Bekbol has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Zaboronok
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan
2 shared publications - Eiichi Ishikawa
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan
2 shared publications - Haolan Yang
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan
2 shared publications - Ilya V. Korolkov
The Institute of Nuclear Physics ARKAE, 050032, Ibragimov str., 1, Almaty, Kazakhstan
2 shared publications - Lana I. Lissovskaya
The Institute of Nuclear Physics, Ibragimov Str. 1, 050032 Almaty, Kazakhstan
2 shared publications - Rafael Iosifivich Shakirzyanov
L.N. Gumilyov Eurasian National University
2 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (16) , 1243
Carborane-Containing Iron Oxide@Gold Nanoparticles for Potential Application in Neutron Capture Therapy
Cancer remains one of the most pressing global health challenges, driving the need for innovative treatment strategies. Boron neutron capture therapy (BNCT) offers a highly selective approach to destroying cancer cells while sparing healthy tissues. To improve boron delivery, Fe3O4@Au nanoparticles were developed and functionalized with a boron-containing carborane compound. Fe3O4 nanoparticles were synthesized and covered by gold, followed by (3-Aminopropyl)triethoxysilane (APTES) modification to introduce amino groups for carborane immobilization. Comprehensive characterization using SEM, DLS, FTIR, EDX, Brunauer–Emmett–Teller (BET), and XRD confirmed successful functionalization at each stage. TEM confirmed the final structure and elemental composition of the nanoparticles. BET analysis revealed a surface area of 94.69 m2/g and a pore volume of 0.51 cm3/g after carborane loading. Initial release studies in PBS demonstrated the removal of only loosely bound carborane within 48 h, with FTIR confirming stable retention of the compound on the nanoparticle surface. The modified nanoparticles achieved a stable zeta potential of −20 mV. The particles showed low toxicity within a range of concentrations (0–300 μg Fe/mL) and were efficiently accumulated by U251MG cells. These results demonstrate the potential of the obtained nanoparticles to carry boron and gold for their possible application as a theranostic agent.
- 13 August 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (16) , 1243
Open AccessCarborane-Containing Iron Oxide@Gold Nanoparticles for Potential Application in Neutron Capture Therapy
Cancer remains one of the most pressing global health challenges, driving the need for innovative treatment strategies. Boron neutron capture therapy (BNCT) offers a highly selective approach to destroying cancer cells while sparing healthy tissues. To improve boron delivery, Fe3O4@Au nanoparticles were developed and functionalized with a boron-containing carborane compound. Fe3O4 nanoparticles were synthesized and covered by gold, followed by (3-Aminopropyl)triethoxysilane (APTES) modification to introduce amino groups for carborane immobilization. Comprehensive characterization using SEM, DLS, FTIR, EDX, Brunauer–Emmett–Teller (BET), and XRD confirmed successful functionalization at each stage. TEM confirmed the final structure and elemental composition of the nanoparticles. BET analysis revealed a surface area of 94.69 m2/g and a pore volume of 0.51 cm3/g after carborane loading. Initial release studies in PBS demonstrated the removal of only loosely bound carborane within 48 h, with FTIR confirming stable retention of the compound on the nanoparticle surface. The modified nanoparticles achieved a stable zeta potential of −20 mV. The particles showed low toxicity within a range of concentrations (0–300 μg Fe/mL) and were efficiently accumulated by U251MG cells. These results demonstrate the potential of the obtained nanoparticles to carry boron and gold for their possible application as a theranostic agent.
- Open Access
- 12 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 797
Synthesis of Gd-DTPA Carborane-Containing Compound and Its Immobilization on Iron Oxide Nanoparticles for Potential Application in Neutron Capture Therapy
Cancer is one of the leading causes of global mortality, and its incidence is increasing annually. Neutron capture therapy (NCT) is a unique anticancer modality capable of selectively eliminating tumor cells within normal tissues. The development of accelerator-based, clinically mountable neutron sources has stimulated a worldwide search for new, more effective compounds for NCT. We synthesized magnetic iron oxide nanoparticles (NPs) that concurrently incorporate boron and gadolinium, potentially enhancing the effectiveness of NCT. These magnetic nanoparticles underwent sequential modifications through silane polycondensation and allylamine graft polymerization, enabling the creation of functional amino groups on their surface. Characterization was performed using Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), energy dispersive X-ray (EDX), dynamic light scattering (DLS), thermal gravimetric analysis (TGA), and transmission electron microscopy (TEM). ICP-AES measurements indicated that boron (B) content in the NPs reached 3.56 ppm/mg, while gadolinium (Gd) averaged 0.26 ppm/mg. Gadolinium desorption was observed within 4 h, with a peak rate of 61.74%. The biocompatibility of the NPs was confirmed through their relatively low cytotoxicity and sufficient cellular tolerability. Using NPs at non-toxic concentrations, we obtained B accumulation of up to 5.724 × 1010 atoms per cell, sufficient for successful NCT. Although limited by its content in the NP composition, the Gd amount may also contribute to NCT along with its diagnostic properties. Further development of the NPs is ongoing, focusing on increasing the boron and gadolinium content and creating active tumor targeting.
- 12 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 797
Open AccessSynthesis of Gd-DTPA Carborane-Containing Compound and Its Immobilization on Iron Oxide Nanoparticles for Potential Application in Neutron Capture Therapy
Cancer is one of the leading causes of global mortality, and its incidence is increasing annually. Neutron capture therapy (NCT) is a unique anticancer modality capable of selectively eliminating tumor cells within normal tissues. The development of accelerator-based, clinically mountable neutron sources has stimulated a worldwide search for new, more effective compounds for NCT. We synthesized magnetic iron oxide nanoparticles (NPs) that concurrently incorporate boron and gadolinium, potentially enhancing the effectiveness of NCT. These magnetic nanoparticles underwent sequential modifications through silane polycondensation and allylamine graft polymerization, enabling the creation of functional amino groups on their surface. Characterization was performed using Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), energy dispersive X-ray (EDX), dynamic light scattering (DLS), thermal gravimetric analysis (TGA), and transmission electron microscopy (TEM). ICP-AES measurements indicated that boron (B) content in the NPs reached 3.56 ppm/mg, while gadolinium (Gd) averaged 0.26 ppm/mg. Gadolinium desorption was observed within 4 h, with a peak rate of 61.74%. The biocompatibility of the NPs was confirmed through their relatively low cytotoxicity and sufficient cellular tolerability. Using NPs at non-toxic concentrations, we obtained B accumulation of up to 5.724 × 1010 atoms per cell, sufficient for successful NCT. Although limited by its content in the NP composition, the Gd amount may also contribute to NCT along with its diagnostic properties. Further development of the NPs is ongoing, focusing on increasing the boron and gadolinium content and creating active tumor targeting.